Indication

In combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non‑small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2208
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
11 November 2019
SMC meeting date:
01 October 2019
Patient group submission deadline:
05 August 2019